Pfizer Declares First-Quarter 2024 Dividend
14 Dezembro 2023 - 6:30PM
Business Wire
Board of Directors approves increase in
quarterly cash dividend to $0.42 per share
Pfizer Inc. (NYSE: PFE) today announced that its board of
directors declared an increase in the quarterly cash dividend on
the company’s common stock to $0.42 for the first-quarter 2024
dividend, payable March 1, 2024, to holders of the Common Stock of
record at the close of business on January 26, 2024. The
first-quarter 2024 cash dividend will be the 341st consecutive
quarterly dividend paid by Pfizer.
“We are pleased to increase our quarterly dividend, which
represents our fifteenth year of consecutive dividend increases,”
said Dr. Albert Bourla, Pfizer Chairman and Chief Executive
Officer. “Our ongoing increases have demonstrated Pfizer’s
commitment to returning value to our shareholders and are a key
part of our capital allocation strategy.”
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this
release is as of December 14, 2023. The Company assumes no
obligation to update forward-looking statements contained in this
release as the result of new information or future events or
developments.
This release contains forward-looking information about the
Company’s quarterly dividend in 2024 and capital allocation
strategy that involves substantial risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. Risks and uncertainties
include, among other things, the uncertainties inherent in research
and development; the uncertainties inherent in business and
financial planning, including, without limitation, risks related to
Pfizer’s business and prospects, adverse developments in Pfizer’s
markets, or adverse developments in the U.S. or global capital
markets, credit markets, regulatory environment or economies
generally; uncertainties regarding the impact of COVID-19 on
Pfizer’s business, operations and financial results; and
competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2022 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
Category: Financial
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231213858048/en/
Media: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226
Investor: IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024